Vascular Cognitive Impairment Mechanistic Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vascular Cognitive Impairment (VCI) encompasses a spectrum of cognitive disorders caused by cerebrovascular disease, ranging from mild cognitive impairment to full dementia. This pathway page describes the mechanistic cascade from vascular injury to cognitive decline, integrating small vessel disease, large vessel disease, and hypoperfusion mechanisms. [1]
Small vessel disease (SVD) is the most common cause of VCI, affecting the small penetrating arteries, arterioles, and capillaries in the brain. Key pathological features include: [2]
The cascade proceeds as follows: [3]
Atherosclerosis of the carotid and intracerebral arteries can cause: [4]
Reduced cerebral perfusion initiates a cascade of events: [5]
| Player | Role | Relevance to VCI | [6]
|--------|------|------------------| [7]
| Endothelin-1 | Vasoconstriction | Elevated in SVD, causes vasoconstriction | [8]
| Matrix Metalloproteinases (MMP-2/9) | BBB degradation | Increased activity breaks down tight junctions | [9]
| Tight Junction Proteins | Claudin-5, Occludin, ZO-1 | Lost in BBB breakdown | [10]
| NG2 | Pericyte marker | Pericyte loss correlates with BBB leak | [11]
| Fazekas Scale | MRI scoring | Quantifies white matter lesion burden | [12]
| White Matter Hyperintensities | MRI marker | Predictor of cognitive decline | [13]
VCI commonly coexists with Alzheimer's disease pathology, leading to mixed dementia: [14]
| Biomarker | Fluid | Change in VCI |
|---|---|---|
| White Matter Hyperintensities | MRI | Increased volume |
| Fractional Anisotropy | DTI | Decreased (axonal loss) |
| Neurofilament Light Chain (NfL) | CSF/Plasma | Elevated |
| Tau | CSF | May be elevated in mixed dementia |
| Aβ42/40 | CSF | May be reduced in mixed dementia |
| Agent | Mechanism | Phase | Status |
|---|---|---|---|
| Clopidogrel | Antiplatelet | Approved | Standard of care |
| Donepezil | Cholinesterase inhibitor | Phase 3 | Mixed results |
| Memantine | NMDA antagonist | Phase 3 | Not effective |
| BMS-98602 | Anti-Aβ | Phase 2 | Mixed dementia |
The study of Vascular Cognitive Impairment Mechanistic Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications advancing our understanding of this mechanism:
Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions. (2024) — Int J Stroke PMID:39283037
Potentially Modifiable Risk Factors for Dementia and Mild Cognitive Impairment: An Umbrella Review and Meta-Analysis. (2024) — Dement Geriatr Cogn Disord PMID:38346414
Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia. (2024) — Hypertension PMID:38044814
Dementia Prevention and Treatment: A Narrative Review. (2024) — JAMA Intern Med PMID:38436963
Vascular Cognitive Impairment. (2024) — Continuum (Minneap Minn) PMID:39620840
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 46%
van der Flier WM, et al. '"Vascular cognitive impairment." Nat Rev Dis Primers'. Nat Rev Dis Primers. 2018. ↩︎
Smith EE, et al. '"Vascular cognitive impairment." Lancet Neurol'. Lancet Neurol. 2020. ↩︎
Pantoni L. '"Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges." Lancet Neurol'. Lancet Neurol. 2010. ↩︎
Wardlaw JM, et al. '"Neuroimaging standards for research into small vessel disease." Lancet Neurol'. Lancet Neurol. 2022. ↩︎
Fazekas F, et al. '"MR signal abnormalities at 1.5 T in Alzheimer''s dementia and normal aging." AJR Am J Roentgenol'. AJR Am J Roentgenol. 1987. ↩︎
Gorelick PB, et al. '"Vascular contributions to cognitive impairment and dementia." Stroke'. Stroke. 2011. ↩︎
Zlokovic BV. '"Neurovascular pathways to neurodegeneration in Alzheimer''s disease and other disorders." Nat Rev Neurosci'. Nat Rev Neurosci. 2011. ↩︎
Iadecola C. '"The neurovascular unit coming of age: a bridge to the blood-brain barrier." Neuron'. Neuron. 2013. ↩︎
Montine TJ, et al. '"National Institute on Aging-Alzheimer''s Association guidelines for the neuropathologic assessment of Alzheimer''s disease." Alzheimers Dement'. Alzheimers Dement. 2012. ↩︎
Schneider JA, et al. '"Mixed brain pathologies account for most dementia cases in community-dwelling older persons." Neurology'. Neurology. 2007. ↩︎
Attems J, Jellinger KA. '"The overlap between vascular disease and Alzheimer disease--clinicopathological studies." Acta Neurol Scand Suppl'. Acta Neurol Scand Suppl. 2009. ↩︎
Sweeney MD, et al. '"Blood-brain barrier: from physiology to disease and back." Physiol Rev'. Physiol Rev. 2019. ↩︎
Toth P, et al. '"Mechanisms of vascular aging." J Gerontol A Biol Sci Med Sci'. J Gerontol A Biol Sci Med Sci. 2019. ↩︎
Arai K, et al. '"Impact of inflammation on cerebrovascular disease." Ann Neurol'. Ann Neurol. 2021. ↩︎